Below are some of the key findings from the market analysis for sickle-cell anemia therapeutics in the US:

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Industry Overview for Sickle-cell Anemia Therapeutics Market in the US

The treatment for sickle-cell anemia requires high-cost medications. Several companies and government organizations are making efforts to reduce the treatment burden on patients by establishing reimbursement policies. For instance, in 2018, Emmaus Medical announced that it had signed a Medicaid Drug Rebate Agreement with the Centers for Medicare and Medicaid Services allowing coverage of Endari. The availability of favorable reimbursement for sickle-cell anemia therapeutics is one of the critical reasons that will propel the sickle-cell anemia therapeutics market in the US in the next five years.

Special drug designations such as orphan drug designations for sickle-cell anemia will drive the sickle-cell anemia therapeutics market in the US to grow at a CAGR of over 15% during the forecast period. There are very few products available in the US for the treatment of sickle-cell anemia. Hence, recently approved drugs will drive market growth.

Top US sickle-cell anemia therapeutics companies covered in this market research report

The sickle-cell anemia therapeutics market in the US is highly concentrated. Market players are leveraging advanced technologies to offer effective sickle-cell anemia therapeutics. By providing a complete analysis of the market’s competitive landscape and with information on the products offered by the companies, this industry analysis report for sickle-cell anemia therapeutics market in the US will allow the clients to identify new growth opportunities and design innovative strategies to improve their share in the market.

The report offers a complete analysis of various companies including:

• Bristol-Myers Squibb
• Emmaus Medical
• Medunik USA

The US Sickle-cell anemia therapeutics market segmentation based on therapy

•  Hydroxyurea
• L-glutamine therapy

The hydroxyurea segment will account for the highest market share of the sickle-cell anemia therapeutics market in the US as hydroxyurea helps in increasing the level of hemoglobin in the body.

Key highlights of the sickle-cell anemia therapeutics market in the US for the forecast years 2018-2022:

• CAGR of the market during the forecast period 2018-2022
• Detailed information on factors that will accelerate the growth of the sickle-cell anemia therapeutics market in the US during the next five years
• Precise estimation of the market size for sickle-cell anemia therapeutics in the US and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the US sickle-cell anemia therapeutics industry across various geographies such as the US
• A thorough analysis of the market’s competitive landscape and detailed information on several vendors
• Comprehensive details on factors that will challenge the growth of the US sickle-cell anemia therapeutics companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch